Professional Documents
Culture Documents
ESSILOR Press Release Crizal Prevencia 28022013 PDF
ESSILOR Press Release Crizal Prevencia 28022013 PDF
(Charenton le Pont, 28 February 2013) - Essilor, world leader in ophthalmic optics, is reinforcing its
commitment to visual health with the launch in 2013 of the first preventive lenses offering selective
protection against harmful blue light -one of the risk factors in retinal cell degeneration- and against UV
rays, which contribute to the development of cataracts. Prevention, such as protecting the eye from
harmful light, is currently the first line of defence against the worldwide problems of age-related macular
degeneration (AMD) and cataracts. These conditions currently affect more than 350 million people around
the world, a figure that may double in the next 30 years with the ageing of the population.
Emitted by the sun and also by artificial light sources such as LEDs and computers or smartphones, blue
light -the range of the visible light spectrum with wavelengths between 380-500 nm- plays a beneficial
role on health, in particular by regulating the internal biological clock. However, a specific band of this
light might have a harmful effect on the eyes.
In order to identify the part of the spectrum that is damaging to the human retina, the joint team
developed a completely new protocol: an in vitro test on retinal cells with narrow screening light exposure
to determine the harmfulness of rays depending on their wavelength. This test -a scientific first in
ophthalmic optics- allowed for the discovery that wavelengths between 415 and 455 nm (spectral band
centered at 435 nm +/- 20nm) are the most harmful for the target retinal cells.
®
After two years of research, the company has developed the Crizal Prevencia™ lens, which is able to
protect the eye from wavelengths that contributes to the degeneration of retinal cells while allowing
beneficial blue light to pass through. This is a new category of preventive lenses developed using Light
Scan™, an exclusive technology which filters light selectively:
- by letting beneficial blue light pass through;
- by filtering out harmful blue-violet rays that can contribute to AMD, as well as UV rays, an important
cause of cataracts;
- while maintaining the transparency of the lens.
Hubert Sagnières, CEO of Essilor International, comments: “This discovery will be a landmark in the field
of optical science and we are very proud to have contributed, alongside Professor Sahel’s research
teams, to this major step forward in the battle against one of the most devastating eye conditions. With
Crizal Prevencia, we are today pioneers in addressing the challenge of preventative innovation. This fits
in fully with Essilor’s strategy of playing a predominant role in the implementation of solutions for better
visual health for everyone, all over the world.”
A
About Essilor
b
The
o world’s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of
u
lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access
t
lenses that meet his or her unique vision requirements. To support this mission, the Company allocates around
P
€150 million to research and development every year, in a commitment to continuously bring new, more effective
a ® ® ® ® TM ®
products
r to market. Essilor’s flagship brands are Varilux , Crizal , Definity , Xperio , Optifog and Foster Grant .
Iti also develops and markets equipment, instruments and services for eyecare professionals.
s
Essilor reported consolidated revenue of €4.2 billion in 2011 and employs around 48,700 people in some 100
V
countries. It operates 19 plants, a total of 390 prescription laboratories and edging facilities, as well as several
i
research
s and development centers around the world.
i
Essilor was classified by Forbes magazine as being among the world’s 30 most innovative companies.
o
For
n more information, please visit www.essilor.com.
The Essilor share trades on the NYSE Euronext Paris market and is included in the EuroStoxx 50 and CAC 40
indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.
About Paris Vision Institute: Paris Vision Institute (UPMC, Inserm, CNRS) is the 1st French research center
dedicated to scientific and medical research on eye diseases. Settled at the heart of the Quinze-Vingts eye
Press Release
hospital, it gathers all the actors of the research around a common objective: accelerate innovation to the benefit
of patients..
Essilor Crizal ® Prevencia™ lenses are Class I medical devices intended for the correction of ametropias and presbyopia and
offering selective protection from harmful blue light and UV rays. In compliance with French law of December 29th, 2011 and with
the decree of May 9th, 2012 Essilor informs you that the above information is general information given as prevention and public
awareness. For more information Essilor invites you to consult a healthcare professional.
Page 2 of 2